Operator
Good morning, everyone and welcome to Grupo Televisa s Fourth Quarter and Full Year 2020 Conference Call.
Before we begin, I would like to draw your attention to the press release, which explains the use of forward-looking statements and applies to everything we discuss in today s call and in the earnings release.
I will now turn the call over to Mr. Alfonso de Angoitia, Co-Chief Executive Officer of Grupo Televisa. Please go ahead, sir.
Alfonso de Angoitia Noriega
Co-Chief Executive Officer
Thank you, DG. Good morning, everyone, and thanks for joining us today.
With me today are Salvi Folch, CEO of Cable; Alex Penna, CEO of Sky; Patricio Wills, Head of Televisa Studios; and Carlos Ferreiro and Antonio Lara, Corporate Vice Presidents of Finance and Administration respectively.
Spain Tourism Office – GCC has appointed Aviareps, a global tourism representation leader, as its joint marketing and public relations representative in Saudi Arabia.
iPolitics By Janet E Silver. Published on Feb 8, 2021 11:08am Parliament Hill on Jan. 15, 2021. (Jolson Lim/iPolitics)
Paytech of Canada is is hoping to kickstart a conversation with the government about the modernization of the current payment system, as well as consumer privacy protections within the financial sector and end-user funds under the Retail Payments Oversight Framework.
The Canadian Payments Act sets out the legal framework for payments and gives oversight to the Minister of Finance.
Paytech’s former executive director
Doug Kreviazuk has registered for the company for these discussions, Alex Vronces replaced Kreviazuk as executive director earlier this month.
The Alliance for Regenerative Medicine: Alliance for Regenerative Medicine Responds to EU Beating Cancer Plan
ATMPs are uniquely positioned to attack cancer at its source, bringing life-changing benefits to patients
BRUSSELS, BELGIUM - February 3, 2021
The Alliance for Regenerative Medicine (ARM) the global voice of the regenerative medicine and advanced therapies sector applauds the EU Beating Cancer Plan s identification of Advanced Therapy Medicinal Products (ATMPs) as part of a comprehensive cancer solution. ATMPs include cell and gene therapies that have already revolutionized the treatment of some aggressive forms of blood cancers and hold great promise for addressing other types of cancer.